

Natasa Jenson, M.D.

Email: drjenson@preferredresearchpartners.com

Phone: 501-553-9987

Research Affiliations

Offices

Preferred Research Partners, Inc.

11219 Financial Centre Parkway, Suite 320

Little Rock, AR 72211

(501) 553-9987

(501) 553-9986 FAX

Preferred Research Partners Arkansas Center for Sleep Medicine

11219 Financial Center Parkway, Suite 101

Little Rock, AR 72211

(501) 553-9987

(501) 553-9986 FAX

EMPLOYMENT

Sub-Investigator

Preferred Research Partners, Inc.
Little Rock, AR 72211

2019-Current

Emergency Medicine Physician

CHI St Vincent
Little Rock, AR

2019- Current

Emergency Medicine Physician

Conway Regional Medical Center
Conway, AR

2018- Current

Emergency Medicine Physician

CHI St Vincent
Hot Springs, AR

2018- Current

Emergency Medicine Physician

Sky Lakes Medical Center
Klamath Falls, OR

2014 - 2018

Resident Physician

Emergency Medicine Department
Loma Linda, CA

2011 - 2014

EDUCATION

- Resident Physician** 2011 - 2014
Loma Linda University Medical Center
Emergency Medicine Department
Loma Linda, CA
- Loma Linda University School of Medicine** 2007 - 2011
Loma Linda, CA
Doctor of Medicine
- Andrews University** 2006 - 2007
Berrien Springs, MI
BS, Biology
- Southwestern Michigan College** 2004 - 2006
Dowagiac, MI
Completed basic science courses
- University of Zagreb School of Medicine** 2003 - 2004
Zagreb, Croatia

RESEARCH PROJECTS AND PUBLICATIONS

- Diagnosis of Necrotizing Fasciitis with Bedside
Ultrasound – the *STAFF* exam** 8/2013
Authors: Erik Castleberg, MD; Natasa Jenson, MD
Vi Am Dinh, MD, RDMS, RDCS
Western Journal of Emergency Medicine; 2013.8.18303
<http://escholarship.org/uc/item/638584rd?view=search>
- Quality Improvement Project: ‘Goal of administering
aspirin to patients presenting with acute coronary syndrome
within 24 hours of arrival to the emergency department’** 2012 - 2014
Loma Linda Department of Emergency Medicine
- Quantifying xanthine oxidase levels in newborns
as a predictor of hypoxic brain injury outcomes.** 2006
Research project with principal Investigator Dr. Danilo Boskovic, PhD
Loma Linda University Department of Biochemistry and Physiology.

TEACHING AND PROFESSIONAL DEVELOPMENT

- Medical School Lectures**
Loma Linda School of Medicine
Cardiopulmonary Arrest 6/2014
Approach to Trauma 6/2014
- Department Lectures:**

Oropharyngeal Cancers	1/2013
Sudden Cardiac Arrest in Children	12/2012
Dermatologic Conditions, a Case Presentation	8/2012
Medical Response to Terrorism Training/Simulation Lab	5/2012
Tension Pneumothorax, a Case Presentation	10/2011

Guest Lectures

Neonatal Resuscitation	11/2012
------------------------	---------

Journal Club Presentation:

Missed and Delayed Diagnoses in the Emergency Department: A Study of Closed Malpractice Claims From 4 Liability Insurers	8/2013
Outpatient treatment of patients with acute pulmonary embolism: the Hestia Study	6/2013

PROFESSIONAL ASSOCIATION MEMBERSHIPS

Alpha Omega Alpha Honor Medical Society	2010 - Present
American College of Emergency Physicians	2010 - Present

LEADERSHIP

Sepsis Treatment Improvement Project Sky Lakes Medical Center Klamath Falls, OR	2017 - Current
Emergency Medicine Interest Group Vice President Loma Linda University School of Medicine	2010 - 2011

References available upon request.

Research Experience

Pharmaceutical:

- **2019: Apnimed-Obstructive Sleep Apnea-APN-002**
- **2019: Aptinyx-Post-Traumatic Stress Disorder-NYX-783-2004**
- **2019: Biohaven Pharmaceuticals -Obsessive Compulsive Disorder-BHV4157- 202**
- **2019: Otsuka Pharmaceuticals -Post Traumatic Stress Disorder-331-201-00071**
- **2019: Takeda-Obstructive Sleep Apnea-Phase 1-TAK-925-2001**
- **2019: LG Chem -Gout with Hyperuricemia -LG-GDCL002**
- **2019: Applied Therapeutics - Diabetic Cardiomyopathy / Stage B Heart Failure at High Risk of Progression to Overt Heart Failure (Stage C Heart Failure)-AT-001-2001**
- **2019: Adare Pharmaceuticals-Eosinophilic Erosive Esophagitis-SP-1011-003**
- **2019: Allergan - Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis-3152-301-002**
- **2019: Allergan-Constipation in Children 6-17 y/o-LIN-MD-64**
- **2019: Allergan-Pediatric Participants with Functional Constipation (FC) or Irritable Bowel Syndrome with Constipation (IBS-C)-LIN-MD-66**

- 2019: Allergan - Pediatric Participants (Age 2 to 5 Years) with Functional Constipation LIN-MD-67
- 2019: Braintree Laboratories - Bowel Prep for Colonoscopy-BLI4900-302
- 2019: Phathom Pharmaceuticals-Erosive Esophagitis-EE-301
- 2019: Phathom Pharmaceuticals-H. Pylori-HP-301
- 2019: Vanda Pharmaceuticals-Diabetic or Idiopathic Gastroparesis-VP-VLY-686-3301
- 2019: Vibrant Ltd-Chronic Idiopathic Constipation-V270
- 2020: Takeda-Idiopathic Hypersomnia-Phase 1 -TAK-925-2002
- 2020: Neurogastrx-Diabetic or Idiopathic Gastroparesis-NGIOI-201
- 2020: Allergan-Major Depressive Disorder-2006-308-008
- 2020: Otsuka -Pediatric Attention Deficit Hyperactivity Disorder -405-201-00010
- 2020: Apnimed -Obstructive Sleep Apnea -APN-006
- 2020: Janssen-Treatment-resistant Depression-54135419TRD4005
- 2020: Janssen -Major Depression & Insomnia-42847922MDD3002
- 2020: Novavax-COVID-19 Vaccine-2019nCoV-301
- 2020: Supemus-ADHD in Preschoolers-812P401
- 2021: Otsuka Pharmaceuticals -ADHD in Children -405-201-00046
- 2021: Apnimed -Obstructive Sleep Apnea -APC-003
- 2021: Apnimed -Obstructive Sleep Apnea -APC-003-OLE
- 2021: Moderna-CMV Vaccine -mRNA-1647-P301
- 2021: Acerus Pharmaceuticals -Ambulatory BP monitoring in Hypogonadism - NAT-2020-01
- 2021: Purdue Pharma LP -ADHD in Preschoolers & Children -ADA4004
- 2021: Apnimed -Obstruction Sleep Apnea-APC-005
- 2021: BlackThorn – MDD with Anhedonia &/or GAD – K2-MDD-201
- 2021: Relmada – Major Depressive Disorder – REL-1017-302
- 2021: Relmada – Major Depressive Disorder – REL-1017-310
- 2021: AbbVie – Pediatric Migraine - 3110-305-002
- 2021: AbbVie – Pediatric Migraine – 3110-306-002
- 2021: Otsuka Pharmaceuticals – ADHD in Children & Adolescents – 405-201-00016
- 2021: Otsuka Pharmaceuticals – ADHD in Children & Adolescents – 405-201-00017
- 2021: Otsuka Pharmaceuticals – ADHD in Children & Adolescents – 405-201-00021
- 2021: Revolo Pharmaceuticals – Eosinophilic Esophagitis – RVLO 121-04
- 2021: Eliem Therapeutics – MDD in Perimenopausal Females – ETX-020155-202
- 2022: Mind Med – Generalized Anxiety Disorder – MMED008
- 2022: Merck – Treatment Resistant Depression – MK1942-006
- 2022: 89 Bio – NASH – BIO89-100-122
- 2022: Phathom Pharmaceuticals – Non-erosive Reflux Disease – NERD-301
- 2022: Alto Neurosciences – PTSD &/or MDD – ALTO-100-001
- 2022: Braintree Laboratories – Erosive Esophagitis – BLI5100-301
- 2022: Braintree Laboratories – Non-erosive Reflux Disease – BLI5100-302
- 2022: Ellodi Pharmaceuticals, L.P. – Eosinophilic Esophagitis – SP-1011-005
- 2022: Hepion Pharmaceuticals. – Non-alcoholic Steatohepatitis – HEPA-CRV431-207
- 2022: Idorsia Pharmaceuticals, Inc. – Pediatric Insomnia – ID-078A205
- 2022: Janssen – Bipolar Depression – 55308942BIP2001
- 2022: Merck – HPV Vaccine & mRNA COVID-19 Vaccine in 9-11 y/o – V503-076
- 2022: Novavax – Pediatric COVID-19 Vaccine – 2019nCoV-503
- 2022: Perception Neuroscience, Inc. – Treatment Resistant Depression – PCN-101-21
- 2022: Phathom Pharmaceuticals – Adolescents with Symptomatic GERD – VPED-102
- 2022: Supernus Pharmaceuticals – Child & Adolescent ADHD – 812P412

- 2023: Alto Neurosciences – MDD – ALTO-100-201
- 2023: AbbVie – Pediatric Episodic Migraine – M21-199
- 2023: AbbVie – Pediatric Episodic Migraine – M21-201
- 2023: Corium – Pediatric ADHD in ages 4-12 y/o – KP415.P01
- 2023: Corium – Pediatric ADHD – KP415.P02
- 2023: CinDome – Adult Diabetic Gastroparesis – CIN-102-123
- 2023: Tonix – Adult Major Depressive Disorder – TNX-TI-M201
- 2023: Tonix- Adult Chronic Migraine – TNX-OX-CM201
- 2023: Braintree Laboratories – Gastroesophageal Reflux Disease – BLI5100-303
- 2023: Phathom Pharmaceuticals – Adolescents with Symptomatic GERD – VPED-103
- 2023: Shionogi – COVID-19 & prevention in household contacts – 226T1331
- 2023: Apnimed – Sleep Apnea – APC-APN-304
- 2023: Lilly – Diabetic Peripheral Neuropathy Pain – J2P-MD-LXBD
- 2023: Supernus – Pre-schooler ADHD – 812P310
- 2023: Supernus / Navitor – Treatment Resistant Major Depressive Disorder – NAV-17A-007
- 2023: Bayer – Sleep Disturbances Associated with Menopause – 22423 (NIRVANA)
- 2023: Usona – Major Depressive Disorder – PSIL301
- 2024: Axsome – Major Depressive Disorder – SOL-MDD-301
- 2024: Axsome – Excessive Daytime Sleepiness with Shift Work Disorder – SOL-SWD-301
- 2024: Axsome – Major Depressive Disorder in Children & Adolescents – AXS-05-MDD-402
- 2024: Axsome – Major Depressive Disorder in Children & Adolescents (extension) – AXS-05-MDD-403
- 2024: AbbVie – Menstrual Migraine Prevention – M23-714
- 2024: Apnimed – Obstructive Sleep Apnea – APC-APN-305
- 2024: MindMed – Generalized Anxiety Disorder – MM120-300/301
- 2024: Apnimed – Obstructive Sleep Apnea – APC-APN-306
- 2024: Vistagen – Social Anxiety Disorder – PH94B-CL043
- 2024: Vanda – Diabetic & Idiopathic Gastroparesis – VP-VLY-686-3303
- 2024: Phathom – Eosinophilic Esophagitis – EoE-201
- 2024: Phathom – Pediatric GERD – VPED-104
- 2024: Alkermes – Narcolepsy – ALKS2680-202
- 2024: Neumora – Major Depressive Disorder – NMRA-335140-301
- 2024: Neumora – Major Depressive Disorder – NMRA-335140-501
- 2024: AbbVie – Migraine Prevention in Adults – M24-873
- 2024: Lilly – Chronic Weight Management & Obstructive Sleep Apnea – J11-MC-GZBK/GSA2
- 2024: Alto Neuroscience – Bipolar Depression – ALTP-100-211
- 2024: VistaGen Therapeutics, Inc. - Social Anxiety Disorder (PALISADE-4) - PH94B-CL043
- 2024: Janssen (J&J) – Adjunctive Treatment for Relapse Prevention in Major Depressive Disorder (MDD) with Moderate to Severe Anhedonia – 67953964MDD3005 (VENTURA-5)
- 2024: Janssen – Adjunctive Therapy in Adult & Elderly Major Depressive Disorder (MDD) with Insomnia - 42847922MDD3003 (OARS-7)
- 2025: Cindome Pharma, Inc. - Idiopathic Gastroparesis – CIN-102-124
- 2025: Phathom Pharmaceuticals, Inc.- Eosinophilic Esophagitis (EoE) – EoE-201

- 2025: Eli Lilly & Company - Moderately to Severely Active Ulcerative Colitis – I7J-MC-DSAG
- 2025: Sanofi-Aventis - Induction study Moderately to Severely Active Ulcerative Colitis – EFC18325
- 2025: Sanofi-Aventis - Induction study Moderately to Severely Active Crohn’s Disease – EFC18326
- 2025: Sanofi-Aventis - Maintenance study - Moderately to Severely Active Crohn’s Disease – EFC18327
- 2025: Sanofi-Aventis - Maintenance Study - Moderately to Severely Active Ulcerative Colitis – EFC18359
- 2025: Mirador Therapeutics, Inc. - Active Crohn’s Disease or Active Ulcerative Colitis (ASCEND-IBD) – MT-100-201/PROBEUC/PROBECD
- 2025: Orion Corporation - Insomnia – 3110012
- 2025: Mind Medicine, Inc. – Major Depressive Disorder (MDD) – MM123-310 (EMERGE)
- 2025: Atai Pharmaceuticals – Treatment Resistant Depression (TRD) – VLS-01-203
- 2025: AbbVie – Pediatric Chronic Migraine ages 12-17 y/o – M23-712
- 2025: Alkermes – Idiopathic Hypersomnia – ALKS2680-203
- 2025: Alkermes – Narcolepsy – ALKS2680-301
- 2025: Mineralys Therapeutics, Inc. – Moderate to Severe Sleep Apnea (OSA) – MLS-101-207
- 2025: Transcend Therapeutics – Post-Traumatic Stress Disorder (PTSD) - TSND201-PTSD-301
- 2025: Axsome Therapeutics – Fibromyalgia – AXS-14-FM-301